AnaptysBio (NASDAQ:ANAB) Shares Gap Down Following Insider Selling

09 Jan 2026, 10:24 by Amy Steele · The Cerbat Gem

AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report)’s share price gapped down before the market opened on Friday after an insider sold shares in the company. The stock had previously closed at $43.80, but opened at $42.75. AnaptysBio shares last traded at $44.45, with a volume of 76,272 shares traded.

Specifically, CFO Dennis Mulroy sold 1,908 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $45.11, for a total value of $86,069.88. Following the completion of the sale, the chief financial officer owned 17,667 shares in the company, valued at $796,958.37. This trade represents a 9.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Daniel Faga sold 9,202 shares of the company’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $45.11, for a total transaction of $415,102.22. Following the transaction, the chief executive officer owned 466,787 shares in the company, valued at $21,056,761.57. The trade was a 1.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In related news, insider Paul F. Lizzul sold 2,235 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $45.11, for a total value of $100,820.85. Following the sale, the insider owned 37,213 shares in the company, valued at $1,678,678.43. This represents a 5.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Guggenheim restated a “buy” rating on shares of AnaptysBio in a research report on Thursday, December 18th. Truist Financial lifted their target price on shares of AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a research report on Monday, November 10th. UBS Group initiated coverage on shares of AnaptysBio in a research report on Wednesday. They issued a “buy” rating and a $70.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of AnaptysBio in a research report on Wednesday, October 8th. Finally, HC Wainwright reduced their price objective on AnaptysBio from $52.00 to $51.00 and set a “buy” rating on the stock in a research report on Monday, November 24th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.40.

Check Out Our Latest Analysis on AnaptysBio

AnaptysBio News Roundup

Here are the key news stories impacting AnaptysBio this week:

Positive Sentiment: UBS reiterated a buy rating and sharply raised its price target to $70 from $20, which can attract fresh institutional and retail buying given the large upgrade in upside expectations. Read More.
Positive Sentiment: AnaptysBio filed a partial motion to dismiss Tesaro/GSK’s anticipatory‑breach claim over Jemperli royalties; a favorable outcome would reduce royalty risk and potential future cash outflows tied to that program. Read More.
Positive Sentiment: The company already has a $100M buyback authorization (up to ~9.6% of shares outstanding), which supports share demand and signals management confidence in intrinsic value. Read More.
Neutral Sentiment: Analyst landscape is mixed but skewed positive: consensus is a “Moderate Buy” with a mean target near $60.40, and several firms have raised targets recently — this provides directional research support but not a guarantee of near‑term moves. Read More.
Neutral Sentiment: Large institutional position changes (significant buys by some funds reported in recent quarters) show continued investor interest at the institutional level; this can limit downside but also concentrate future flows. Read More.
Negative Sentiment: Several insiders sold material stakes this week — CEO Daniel Faga sold ~9,202 shares (~$662k), CFO Dennis Mulroy sold 1,908 shares (~$86k) and other executives also sold sizable blocks — these coordinated disclosures are pressuring sentiment and may increase near‑term selling. Read More. Read More.

AnaptysBio Stock Performance

The firm has a fifty day simple moving average of $42.46 and a 200 day simple moving average of $31.30. The company has a market cap of $1.24 billion, a PE ratio of -15.76 and a beta of 0.32.

AnaptysBio (NASDAQ:ANAB – Get Free Report) last released its earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $1.58. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. The business had revenue of $76.32 million for the quarter, compared to analysts’ expectations of $15.83 million. As a group, equities analysts predict that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio declared that its Board of Directors has authorized a share buyback plan on Friday, November 21st that permits the company to repurchase $100.00 million in outstanding shares. This repurchase authorization permits the biotechnology company to reacquire up to 9.6% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

Institutional Investors Weigh In On AnaptysBio

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC lifted its stake in shares of AnaptysBio by 153.3% in the 1st quarter. AQR Capital Management LLC now owns 30,011 shares of the biotechnology company’s stock valued at $558,000 after purchasing an additional 18,165 shares in the last quarter. Woodline Partners LP lifted its position in AnaptysBio by 63.1% during the first quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company’s stock valued at $14,705,000 after buying an additional 305,950 shares in the last quarter. Rhumbline Advisers increased its position in shares of AnaptysBio by 2.7% in the first quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company’s stock worth $574,000 after acquiring an additional 826 shares in the last quarter. Voya Investment Management LLC purchased a new position in shares of AnaptysBio in the 1st quarter valued at $1,803,000. Finally, HighMark Wealth Management LLC lifted its holdings in shares of AnaptysBio by 58.2% during the 2nd quarter. HighMark Wealth Management LLC now owns 145,550 shares of the biotechnology company’s stock valued at $3,231,000 after acquiring an additional 53,550 shares in the last quarter.

About AnaptysBio

(Get Free Report)

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.